Indefinite Delivery Contract HHSN261201200021I
Award Date
9/20/12
Last Date to Order
9/19/14
Federal Agency
National Cancer Institute
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to the University of Alabama at Birmingham (UAB) to support the agency's Preclinical Prevent Cancer Program. The program focuses on evaluating the preclinical efficacy and identifying intermediate biomarkers for potential cancer prevention agents prior to clinical trials. Under this $29.8 million multiple-award IDC, UAB has been issued multiple...
This is a multiple award Indefinite Delivery Contract (IDC) issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services. The contract has a ceiling value of $9,950,000 and was awarded to the University of Oklahoma (OU) to provide preclinical research and development services related to cancer prevention and treatment. The task orders issued under this IDC cover a range of preclinical oncology research activities, including the evaluation of...
The federal contract IDV award is an Indefinite Delivery Contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU). The contract vehicle is titled "Preclinical Agent Development Assays 2012-2016" and has a ceiling value of $9,900,000. Under this IDIQ contract, OU has been issued multiple delivery orders totaling over $4.8 million to conduct preclinical research and development...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS). The contract, valued at up to $74,995,000, is a multiple award with Advanced Bioscience Laboratories, Inc. (ABL) as the prime contractor. The contract supports the PREVENT Cancer Preclinical Drug Development Program, with the objective of cGMP production of vaccines and biologicals for cancer prevention. Key...
This indefinite delivery contract (IDC) was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson). The $149,995,000 multiple-award IDIQ contract supports the NCI's "PREVENT Cancer Preclinical Drug Development Program" and covers preclinical efficacy and biomarker evaluation of potential cancer preventive agents. Under this IDC, MD Anderson has been awarded a $1,144,300...
The National Cancer Institute (NCI) awarded a multiple-award Indefinite Delivery Contract (IDC) with a $149,995,000 ceiling value to The Institute For Cancer Research, a non-profit organization and subsidiary of Temple University, to provide preclinical efficacy and biomarker analysis services in support of the PREVENT Cancer Preclinical Drug Development Program. This 5-year IDC contract includes three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product...
This Indefinite Delivery Contract (IDC) was awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The contract, with a ceiling value of $0, is part of the Preclinical Agent Development Assays 2012-2016 program and supports preclinical in vitro and in vivo agent development assays. Under this IDC, IITRI provides a range of preclinical research...
The contract IDV award is for the PREVENT Cancer Preclinical Drug Development Program, a multiple-award IDIQ contract administered by the National Cancer Institute (NCI). The program encompasses three main technical areas: (1) evaluation of the efficacy and pharmacodynamic/efficacy biomarkers for potential cancer preventive agents, (2) preclinical product development, analytical testing, process development, and cGMP manufacturing support for cancer preventive vaccines, and (3) pharmacological...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), a civilian agency under the Department of Health and Human Services, to the University of Oklahoma (OU) to support the PREVENT Cancer Preclinical Drug Development Program. The $149,995,000 IDIQ contract covers the continued evaluation of the efficacy and pharmacodynamic/efficacy biomarkers of potential cancer preventive agents, as well as preclinical product development, manufacturing, and...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $74,995,000 multiple-award contract, titled the "PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers," supports preclinical efficacy and biomarker evaluation, manufacturing, and...
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Completion Date (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
Delivery Order HHSN261201200021I-HHSN26100002 | University Of Alabama At Birmingham | $669.2k | 9/20/12 | 9/19/15 | 5/6/15 | |
Delivery Order HHSN261201200021I-HHSN26100001 | University Of Alabama At Birmingham | $2.3k | 9/20/12 | 9/19/13 | 9/20/12 | |
Delivery Order HHSN261201200021I-HHSN26100006 | University Of Alabama At Birmingham | $487.2k | 8/26/14 | 8/25/17 | 6/21/19 | |
Delivery Order HHSN261201200021I-HHSN26100004 | University Of Alabama At Birmingham | $392.7k | 9/18/13 | 9/17/16 | 9/18/17 | |
Delivery Order HHSN261201200021I-HHSN26100007 | University Of Alabama At Birmingham | $544.5k | 9/12/14 | 9/11/17 | 6/21/19 |